---
title: "Faeth Therapeutics CFO Brian C. Stephenson reports $489,159 common share purchase"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291015452.md"
description: "Faeth Therapeutics CFO Brian C. Stephenson purchased 18,641 common shares on the open market for $489,159. Share prices ranged from $23.61 to $27.77. Following these indirect purchases, his total common stock holdings increased to 33,054 shares."
datetime: "2026-06-26T23:41:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291015452.md)
  - [en](https://longbridge.com/en/news/291015452.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291015452.md)
---

# Faeth Therapeutics CFO Brian C. Stephenson reports $489,159 common share purchase

-   Faeth Therapeutics CFO Brian C. Stephenson reported open-market purchases of 18,641 common shares held indirectly. \* Prices ranged from $23.61 to $27.77 per share across the reported buys. \* Indirect holdings in common stock rose to 33,054 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001780030-26-000005), on June 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)

## Related News & Research

- [Faeth Therapeutics files initial beneficial ownership statement for Khosla Ventures VI, L.P](https://longbridge.com/en/news/294108113.md)
- [Faeth Therapeutics CFO Brian C. Stephenson acquires USD 319,293 of common shares](https://longbridge.com/en/news/291473235.md)
- [Scribe Therapeutics CFO David Parrot reports $ 39,990 common stock acquisition](https://longbridge.com/en/news/293991409.md)
- [Bicara Therapeutics director Christy J. Oliger files initial beneficial ownership statement](https://longbridge.com/en/news/294255131.md)
- [Polaryx Therapeutics announces annual shareholder meeting](https://longbridge.com/en/news/294114055.md)